Zealand Pharma A/S ZEAL.CO
Composite 60/100; the shares have moved about 80% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 9/100 — a strong mark against it.
Balance-sheet strength ranks 96/100 — a strong point in its favour. Quality ranks 78/100 — a strong point in its favour. Valuation ranks 72/100 — a moderate point in its favour.
Growth ranks 9/100 — a strong mark against it. Momentum ranks 17/100 — a strong mark against it.
What the company does Zealand Pharma discovers, develops, and commercializes peptide-based medicines for gastrointestinal, metabolic, and specialty diseases. Key products include Zegalogue for severe hypoglycemia and Dasiglucagon for congenital hyperinsulinism. The pipeline features glepaglutide in Phase III trials for short bowel syndrome.
Key financials Zealand reports exceptional profitability: ROE 56%, ROA 35%, ROCE 46%, and net margin 69%. Revenue grew 325% while EPS growth is 0%. Debt/equity is 0.03, interest coverage 184x, and current ratio 37x, indicating strong financial health.
Stock health SideraVia scores Zealand 71/100: quality 81, strength 98, valuation 87, but weak momentum at 22. Gross margins are 100%, EV/EBITDA 1.0x, and FCF yield 20%. RSI(14) is 57, suggesting neutral technical momentum.
Price vs fair value The stock trades at a **discount** of 34.40% to our fair-value estimate and a **discount** of 45.64% to the 12-month target. - Fair-value estimate implies 34.40% upside (SideraVia) - 12-month target suggests 45.64% upside (analyst count 14) - Valuation percentile 87/100 (top quintile) - EV/EBITDA 0.99x (deep value) - Momentum percentile 22/100 (weak)
Looking forward Zealand’s pipeline progress—particularly glepaglucagon’s Phase III readout—will likely drive valuation re-rating. Analysts cite near-term catalysts in metabolic disease as key triggers for multiple expansion.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.